ClinicalTrials.gg
CompletedNCT00697801Updated Jan 9, 2014Results posted

Study of MAP0010 in Asthmatic Children and Adolescents

A Phase 2 interventional study of MAP0010 low dose and MAP0010 high dose in Asthma, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
46th of 108
208 · median 124
Started
2006
with 7 others
Phase 2
5 of 110
none open now
Registered
55th of 110
by date
Lead sponsor
5 of 110
Allergan

Among the 110 studies testing budesonide in Asthma, this one is the 46th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2006, is one of 5 in phase 2, and was the 55th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female asthmatic children/adolescents
  • 1 to 18 years of age
  • greater than or equal to 50% predicted normal (where obtainable)
  • Stable but symptomatic
  • Diagnosis of asthma (per NIH criteria) at least 3 months before screening OR documented exacerbation or worsening of asthma or symptoms suggestive of asthma including nocturnal asthma, within 6 months of screening OR documented SAB use more than or at least once for symptom relief during the 4 days of run in with a total symptom score greater than or equal to 1 OR greater than or equal to 1 night disturbed due to asthma symptoms in previous month.

Exclusion criteria

Exclusion Criteria:

  • Any other significant childhood illness.
  • Participated in any clinical trial within the 30 days prior to screening.
  • Use of any within 2 weeks of screening.
  • Use of oral corticosteroid within 30 days of screening or prolonged use of oral corticosteroids within 12 weeks of screening.
  • Use of inhaled long acting bronchodilators.
  • Presumptive or documented history of upper or lower respiratory infection within 2 weeks before screening.
  • Any history of acute or severe asthma attack requiring ICU admission or ventilatory support.
  • History suggestive (or diagnosis) of other concomitant lung disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    MAP0010 low dose

    a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks

    Drug: MAP0010 low dose

  • Experimental
    MAP0010 high dose

    a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks

    Drug: MAP0010 high dose

  • Placebo comparator
    Placebo

    Placebo delivered by nebulization twice daily for 6 weeks

    Drug: Placebo

Interventions

  • a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks

  • a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks

  • DrugPlacebo

    Placebo delivered by nebulization twice daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Daytime Composite Symptom Score

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

    Time frame: baseline, week 6

  2. Change From Baseline in Nighttime Composite Symptom Score

    The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

    Time frame: baseline, week 6

Secondary outcomes

  1. Change From Baseline in FEV1% Predicted

    The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).

    Time frame: baseline, week 6

07

Results

Posted Oct 23, 2013

Participant flow

Participant flow — Overall Study
MilestoneMAP0010 High DoseMAP0010 Low DosePlacebo
Started697069
Completed575845
Not completed121224

Outcome measures

PrimaryChange From Baseline in Daytime Composite Symptom Score

The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in Daytime Composite Symptom Score
units on a scaleMAP0010 High DoseMAP0010 Low DosePlacebo
Baseline3.1 ± 1.902.8 ± 1.752.6 ± 1.59
Change from Baseline at week 6-0.7 ± 1.80-1.4 ± 1.48-0.6 ± 1.63
PrimaryChange From Baseline in Nighttime Composite Symptom Score

The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath. The individual symptoms were scored using a four point scale: 0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.

Time frame:
baseline, week 6
Reported as:
Mean · units on a scale
Change From Baseline in Nighttime Composite Symptom Score
units on a scaleMAP0010 High DoseMAP0010 Low DosePlacebo
Baseline2.7 ± 1.962.4 ± 1.752.4 ± 1.49
Change from Baseline at week 6-0.6 ± 2.00-1.2 ± 1.42-0.4 ± 1.60
SecondaryChange From Baseline in FEV1% Predicted

The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).

Time frame:
baseline, week 6
Reported as:
Mean · percentage of predicted FEV1
Change From Baseline in FEV1% Predicted
percentage of predicted FEV1MAP0010 High DoseMAP0010 Low DosePlacebo
Baseline74.8 ± 11.4573.8 ± 13.1065.9 ± 7.22
Change from Baseline at 6 weeks6.3 ± 9.876.3 ± 7.735.9 ± 8.73

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MAP0010 High Dose—0/69 (0%)21/69 (30.4%)
MAP0010 Low Dose—0/67 (0%)10/67 (14.9%)
Placebo—0/69 (0%)20/69 (29%)
Most frequent other events
Most frequent other events
EventMAP0010 High DoseMAP0010 Low DosePlacebo
Upper Respiratory InfectionInfections and infestations8/696/6712/69
AsthmaRespiratory, thoracic and mediastinal disorders7/692/675/69
NasopharyngitisInfections and infestations6/692/673/69

Baseline characteristics

The baseline characteristics are summarized on the Intent-to-treat population (those patients with at least 1 on treatment efficacy evaluation including 1 electronic diary entry).

Age, Continuous
Age, Continuous(years)MAP0010 High DoseMAP0010 Low DosePlaceboTotal
Mean10.2 ± 4.7610.5 ± 4.7510.2 ± 4.5210.3 ± 4.68
Sex: Female, Male
Sex: Female, Male(Participants)MAP0010 High DoseMAP0010 Low DosePlaceboTotal
Female27252072
Male414045126
08

Study locations

1 site
  • San Diego, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2008
First posted
Jun 16, 2008
Start
Jul 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results first posted
Oct 23, 2013
Last update
Jan 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00697801
Lead sponsor
Allergan
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Responsible party
Sponsor
First posted
Jun 16, 2008
Start date
Jul 2006
Primary completion
Dec 2006
Completion
Dec 2006
Results posted
Oct 23, 2013
Last update
Jan 9, 2014

Study contacts

Medical Director
study director · MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion